FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163533907> ?p ?o ?g. }

• W2163533907 endingPage "789" @default.
• W2163533907 startingPage "781" @default.
• W2163533907 abstract "BackgroundProlonged cross-clamp time during cardiac surgery increases the risk of postoperative mortality and myocardial injury. This subanalysis from the pexelizumab for reduction of infarction and mortality in coronary artery bypass grafting surgery (PRIMO-CABG) trial, a phase III double-blind, placebo-controlled study of 3,099 patients undergoing on-pump coronary artery bypass graft surgery with or without valve surgery, assessed the impact of pexelizumab, an investigational C5 complement inhibitor, on postoperative outcomes after prolonged aortic cross-clamp time.MethodsThe composite endpoint of death or myocardial infarction through postoperative day 30 and death alone through days 30, 90, and 180 were examined in subpopulations of patients across different cross-clamp times.ResultsAfter prolonged cross-clamping (≥90 minutes), death, or myocardial infarction through day 30 and death through days 30, 90, and 180 were significantly increased in the intent-to-treat population and were even higher in patients with two or more prespecified risk factors, compared with all patients cross-clamped less than 90 minutes. Pexelizumab significantly reduced the incidence of death or myocardial infarction through day 30, and significantly reduced the incidence of mortality through day 180, in patients with two or more risk factors that required prolonged cross-clamp time. Pexelizumab also significantly reduced perioperative myocardial injury in all patients requiring prolonged cross-clamp time.ConclusionsIn this retrospective, subgroup analysis, pexelizumab reduced postoperative morbidity and myocardial injury in patients with multiple risk factors who underwent prolonged cross-clamp time during coronary artery bypass surgery. The clinical benefit of pexelizumab may be related to the effect of complement inhibition in the presence of potential ischemic-reperfusion injury associated with prolonged aortic cross-clamp time. Prolonged cross-clamp time during cardiac surgery increases the risk of postoperative mortality and myocardial injury. This subanalysis from the pexelizumab for reduction of infarction and mortality in coronary artery bypass grafting surgery (PRIMO-CABG) trial, a phase III double-blind, placebo-controlled study of 3,099 patients undergoing on-pump coronary artery bypass graft surgery with or without valve surgery, assessed the impact of pexelizumab, an investigational C5 complement inhibitor, on postoperative outcomes after prolonged aortic cross-clamp time. The composite endpoint of death or myocardial infarction through postoperative day 30 and death alone through days 30, 90, and 180 were examined in subpopulations of patients across different cross-clamp times. After prolonged cross-clamping (≥90 minutes), death, or myocardial infarction through day 30 and death through days 30, 90, and 180 were significantly increased in the intent-to-treat population and were even higher in patients with two or more prespecified risk factors, compared with all patients cross-clamped less than 90 minutes. Pexelizumab significantly reduced the incidence of death or myocardial infarction through day 30, and significantly reduced the incidence of mortality through day 180, in patients with two or more risk factors that required prolonged cross-clamp time. Pexelizumab also significantly reduced perioperative myocardial injury in all patients requiring prolonged cross-clamp time. In this retrospective, subgroup analysis, pexelizumab reduced postoperative morbidity and myocardial injury in patients with multiple risk factors who underwent prolonged cross-clamp time during coronary artery bypass surgery. The clinical benefit of pexelizumab may be related to the effect of complement inhibition in the presence of potential ischemic-reperfusion injury associated with prolonged aortic cross-clamp time." @default.
• W2163533907 created "2016-06-24" @default.
• W2163533907 creator A5012843747 @default.
• W2163533907 creator A5021979803 @default.
• W2163533907 creator A5022745714 @default.
• W2163533907 creator A5039027133 @default.
• W2163533907 creator A5042536098 @default.
• W2163533907 creator A5050167063 @default.
• W2163533907 creator A5053864173 @default.
• W2163533907 creator A5063055453 @default.
• W2163533907 creator A5063067802 @default.
• W2163533907 creator A5079856600 @default.
• W2163533907 creator A5090147492 @default.
• W2163533907 date "2006-09-01" @default.
• W2163533907 modified "2023-10-16" @default.
• W2163533907 title "Effect of Pexelizumab in Coronary Artery Bypass Graft Surgery With Extended Aortic Cross-Clamp Time" @default.
• W2163533907 cites W153696573 @default.
• W2163533907 cites W1990174952 @default.
• W2163533907 cites W1993047043 @default.
• W2163533907 cites W2003521961 @default.
• W2163533907 cites W2033317854 @default.
• W2163533907 cites W2041156861 @default.
• W2163533907 cites W2043167284 @default.
• W2163533907 cites W2045734717 @default.
• W2163533907 cites W2053057113 @default.
• W2163533907 cites W2064695631 @default.
• W2163533907 cites W2070889150 @default.
• W2163533907 cites W2079322072 @default.
• W2163533907 cites W2101396622 @default.
• W2163533907 cites W2105013990 @default.
• W2163533907 cites W2116638495 @default.
• W2163533907 cites W2120795994 @default.
• W2163533907 cites W2145201337 @default.
• W2163533907 cites W2148679018 @default.
• W2163533907 cites W2161215909 @default.
• W2163533907 cites W2166212676 @default.
• W2163533907 cites W2274989724 @default.
• W2163533907 cites W85213532 @default.
• W2163533907 cites W923764892 @default.
• W2163533907 doi "https://doi.org/10.1016/j.athoracsur.2006.02.024" @default.
• W2163533907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16928483" @default.
• W2163533907 hasPublicationYear "2006" @default.
• W2163533907 type Work @default.
• W2163533907 sameAs 2163533907 @default.
• W2163533907 citedByCount "28" @default.
• W2163533907 countsByYear W21635339072013 @default.
• W2163533907 countsByYear W21635339072014 @default.
• W2163533907 countsByYear W21635339072015 @default.
• W2163533907 countsByYear W21635339072016 @default.
• W2163533907 countsByYear W21635339072021 @default.
• W2163533907 countsByYear W21635339072022 @default.
• W2163533907 crossrefType "journal-article" @default.
• W2163533907 hasAuthorship W2163533907A5012843747 @default.
• W2163533907 hasAuthorship W2163533907A5021979803 @default.
• W2163533907 hasAuthorship W2163533907A5022745714 @default.
• W2163533907 hasAuthorship W2163533907A5039027133 @default.
• W2163533907 hasAuthorship W2163533907A5042536098 @default.
• W2163533907 hasAuthorship W2163533907A5050167063 @default.
• W2163533907 hasAuthorship W2163533907A5053864173 @default.
• W2163533907 hasAuthorship W2163533907A5063055453 @default.
• W2163533907 hasAuthorship W2163533907A5063067802 @default.
• W2163533907 hasAuthorship W2163533907A5079856600 @default.
• W2163533907 hasAuthorship W2163533907A5090147492 @default.
• W2163533907 hasBestOaLocation W21635339071 @default.
• W2163533907 hasConcept C126322002 @default.
• W2163533907 hasConcept C127413603 @default.
• W2163533907 hasConcept C141071460 @default.
• W2163533907 hasConcept C164705383 @default.
• W2163533907 hasConcept C2776161997 @default.
• W2163533907 hasConcept C2776483784 @default.
• W2163533907 hasConcept C2776820930 @default.
• W2163533907 hasConcept C2908647359 @default.
• W2163533907 hasConcept C31174226 @default.
• W2163533907 hasConcept C42219234 @default.
• W2163533907 hasConcept C500558357 @default.
• W2163533907 hasConcept C71924100 @default.
• W2163533907 hasConcept C78519656 @default.
• W2163533907 hasConcept C84111939 @default.
• W2163533907 hasConcept C99454951 @default.
• W2163533907 hasConceptScore W2163533907C126322002 @default.
• W2163533907 hasConceptScore W2163533907C127413603 @default.
• W2163533907 hasConceptScore W2163533907C141071460 @default.
• W2163533907 hasConceptScore W2163533907C164705383 @default.
• W2163533907 hasConceptScore W2163533907C2776161997 @default.
• W2163533907 hasConceptScore W2163533907C2776483784 @default.
• W2163533907 hasConceptScore W2163533907C2776820930 @default.
• W2163533907 hasConceptScore W2163533907C2908647359 @default.
• W2163533907 hasConceptScore W2163533907C31174226 @default.
• W2163533907 hasConceptScore W2163533907C42219234 @default.
• W2163533907 hasConceptScore W2163533907C500558357 @default.
• W2163533907 hasConceptScore W2163533907C71924100 @default.
• W2163533907 hasConceptScore W2163533907C78519656 @default.
• W2163533907 hasConceptScore W2163533907C84111939 @default.
• W2163533907 hasConceptScore W2163533907C99454951 @default.
• W2163533907 hasIssue "3" @default.
• W2163533907 hasLocation W21635339071 @default.
• W2163533907 hasLocation W21635339072 @default.
• W2163533907 hasOpenAccess W2163533907 @default.

• next